サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1574950

ペプチド抗生物質市場：製品タイプ別、疾患別、投与経路別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Peptide Antibiotics Market, By Product Type, By Disease, By Route of Administration, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.32円
ペプチド抗生物質市場：製品タイプ別、疾患別、投与経路別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

ペプチド抗生物質の市場規模は、2023年に48億409万米ドルとなり、2024年から2032年にかけてCAGR11.20%で拡大すると予測されています。

ペプチド抗生物質市場 - 市場力学

抗生物質耐性の増加は、ペプチド抗生物質イノベーションの需要を促進します。

抗生物質耐性の増加は、ペプチド抗生物質の需要を増加させている大きな問題です。米国疾病予防管理センター（CDC）によると、米国では毎年280万人以上の抗生物質耐性感染症が発生しており、35,000人以上が死亡しています。これは深刻な問題であり、多くの一般的な抗生物質が効かなくなっているため、新しい治療法が必要であることを示しています。

ペプチド抗生物質は良い解決策になるかもしれません。ペプチド抗生物質は通常の抗生物質とは異なる働きをするため、研究者たちは抗生物質耐性と闘うためにその特殊な性質を調べています。これらのユニークな特性により、ペプチド抗生物質は耐性菌に有効であり、感染症を制御するためのより良い方法への希望を与えてくれます。

ペプチド抗生物質市場 - 主要洞察

弊社のリサーチアナリストの分析によると、世界市場は予測期間（2024年～2032年）に約11.20%のCAGRで毎年成長すると推定されます。

製品タイプ別では、リボソーム合成ペプチド抗生物質が2023年に最大の市場シェアを示すと予測されています。

疾患別では、皮膚感染症が2023年の主要タイプでした。

投与経路別では、2023年には注射剤が主要タイプでした。

地域別では、北米が2023年の売上高でトップでした。

ペプチド抗生物質市場 - セグメンテーション分析：

ペプチド抗生物質の世界市場は、製品タイプ、疾患、投与経路、地域に基づいてセグメント化されます。

市場は製品タイプによって2つのカテゴリーに分けられます：リボソーム合成ペプチド抗生物質と非リボソーム合成ペプチド抗生物質です。リボソーム合成ペプチド抗生物質は最も顕著なセグメントです。これは主に、様々な感染症、特にグラム陽性菌による感染症によく効くからです。また、経口摂取が容易であることが多く、患者が治療に従いやすいという利点もあります。抗生物質耐性菌の増加に伴い、これらの抗生物質についてより多くの調査が行われ、新しい効果的な選択肢が生まれています。重篤な感染症を治療できる抗生物質は、医師と患者の双方に利益をもたらし、市場の重要な部分を占めています。

市場は疾患別に2つのカテゴリーに分けられます：皮膚感染、HABP/VABP、血流感染、その他です。皮膚感染症分野が最も顕著です。皮膚感染症は一般的であり、さまざまな細菌によって引き起こされる可能性があるため、効果的な治療が不可欠です。ペプチド抗生物質はこれらの細菌を効果的に標的とするため、頻繁に使用されています。皮膚感染症は広く蔓延しており、放置すればより深刻な合併症を引き起こす可能性があるため、これらの抗生物質に対する需要は高いです。このような皮膚感染症の治療への注目は、市場の成長を促進し、ヘルスケアプロバイダーと患者の両方をサポートするのに役立っています。

ペプチド抗生物質市場 - 地理的洞察

北米のペプチド抗生物質市場は急成長しています。この成長の背景には、薬剤耐性菌と戦うための新しい抗生物質に対するニーズの高まりがあります。多くの病院やヘルスケアプロバイダーが効果的な治療法を求めています。この分野の研究開発はより多くの資金を獲得しており、新しいペプチド抗生物質の創出に役立っています。

さらに、こうした治療の利点に対する認識が、医師や患者の間に広まりつつあります。また、技術革新を奨励する規制の枠組みも市場を支えています。全体として、北米はペプチド抗生物質産業における主要プレーヤーになりつつあります。

ペプチド抗生物質市場 - 競合情勢：

ペプチド抗生物質市場は競争が激しく、Baxter International、Novartis、Merckなどの主要企業が市場をリードしています。これらの企業は、耐性菌の増加に対処するため、新しく効果的な抗生物質の開発に注力しています。AstraZenecaやBoehringer Ingelheimのような企業も、製品提供の革新と改善のために研究に投資しています。SandozとHikma Pharmaceuticalsはジェネリック医薬品に特化し、治療をより身近なものにしています。一方、AmgenとGilead Sciencesは、特定の医療ニーズに対応する独自の治療法に注力しています。全体として、これらの企業は世界ヘルスの課題に対処するため、協力、調査、製品ラインナップの拡大を通じてその地位を高めようと努力しています。

目次

第1章 ペプチド抗生物質市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 ペプチド抗生物質の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 ペプチド抗生物質産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 ペプチド抗生物質市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 ペプチド抗生物質市場情勢

  • ペプチド抗生物質市場シェア分析、2023年
  • 内訳データ：主要メーカー別
    • 既存企業の分析
    • 新興企業の分析

第7章 ペプチド抗生物質市場：製品タイプ別

  • 概要
    • セグメントシェア分析：製品タイプ別
    • リボソーム合成ペプチド抗生物質
    • 非リボソーム合成ペプチド抗生物質

第8章 ペプチド抗生物質市場：疾患別

  • 概要
    • セグメントシェア分析：疾患別
    • 皮膚感染症
    • HABP/VABP
    • 血流感染症
    • その他

第9章 ペプチド抗生物質市場：投与経路別

  • 概要
    • セグメントシェア分析：投与経路別
    • 傾向
    • 注射剤
    • 局所
    • その他

第10章 ペプチド抗生物質市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：ペプチド抗生物質業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Baxter International Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • Boehringer Ingelheim GmbH
    • Fujifilm Diosynth Biotechnologies
    • Hikma Pharmaceuticals PLC
    • Polymun Scientific GmbH
    • Sandoz International GmbH（a Novartis division）
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Amgen Inc.
    • Gilead Sciences, Inc.
    • Hoffmann-La Roche Ltd.
    • Vitae Pharmaceuticals, Inc.
    • Thermo Fisher Scientific Inc.
    • CureVac AG

第12章 アナリストの全方位展望

目次
Product Code: ANV3953

REPORT HIGHLIGHT

Peptide Antibiotics Market size was valued at USD 4,804.09 Million in 2023, expanding at a CAGR of 11.20% from 2024 to 2032.

The peptide antibiotics market involves the development and sale of antibiotics made from small proteins called peptides. These antibiotics are effective against bacteria and can help treat infections, especially those resistant to traditional antibiotics. The market is growing due to increasing bacterial resistance and the need for new treatments. Researchers are exploring different peptides to find new drugs that are safe and effective. This area of medicine is important for public health as it offers hope in the fight against stubborn infections. Overall, peptide antibiotics represent a promising solution in the battle against antibiotic resistance.

Peptide Antibiotics Market- Market Dynamics

Increasing antibiotic resistance drives demand for peptide antibiotics innovation.

The rise of antibiotic resistance is a big problem that is increasing the demand for peptide antibiotics. According to the Centers for Disease Control and Prevention (CDC), there are more than 2.8 million antibiotic-resistant infections in the U.S. every year, leading to over 35,000 deaths. This is a serious issue and shows we need new treatments because many common antibiotics no longer work well.

Peptide antibiotics could be a good solution. They work differently than regular antibiotics, and researchers are looking into their special features to fight antibiotic resistance. These unique properties make peptide antibiotics effective against resistant bacteria, giving us hope for better ways to control infections.

Peptide Antibiotics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.20% over the forecast period (2024-2032)

Based on product type segmentation, Ribosomal Synthesized Peptide Antibiotics was predicted to show maximum market share in the year 2023

Based on Disease segmentation, Skin Infection was the leading type in 2023

Based on Route of Administration segmentation, Injectables was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Peptide Antibiotics Market- Segmentation Analysis:

The Global Peptide Antibiotics Market is segmented based on Product Type, Disease, Route of Administration, and Region.

The market is divided into two categories based on Product Type: Ribosomal Synthesized Peptide Antibiotics, and Non-Ribosomal Synthesized Peptide Antibiotics. Ribosomal Synthesized Peptide Antibiotics are the most prominent segment. This is mainly because they work well against various infections, especially those caused by Gram-positive bacteria. They are often easier to take by mouth, which makes patients more likely to follow their treatment. With the rise of antibiotic-resistant bacteria, more research is being done on these antibiotics, leading to new and effective options. Their ability to treat serious infections makes them a key part of the market, benefiting both doctors and patients.

The market is divided into two categories based on Disease: Skin Infection, HABP/VABP, Blood Stream Infection, and Others. The skin infection segment is the most prominent. Skin infections are common and can be caused by a variety of bacteria, making effective treatments essential. Peptide antibiotics are frequently used because they effectively target these bacteria. Since skin infections are widespread and can lead to more serious complications if left untreated, there is a strong demand for these antibiotics. This focus on treating skin infections helps drive growth in the market and supports both healthcare providers and patients.

Peptide Antibiotics Market- Geographical Insights

The peptide antibiotics market in North America is growing rapidly. This rise is due to the increasing need for new antibiotics to fight drug-resistant bacteria. Many hospitals and healthcare providers are looking for effective treatments. Research and development in this area are getting more funding, which helps create new peptide antibiotics.

Moreover, awareness of the benefits of these treatments is spreading among doctors and patients. The market is also supported by regulatory frameworks that encourage innovation. Overall, North America is becoming a key player in the peptide antibiotics industry.

Peptide Antibiotics Market- Competitive Landscape:

The peptide antibiotics market is highly competitive, with key players like Baxter International, Novartis, and Merck leading the way. These companies focus on developing new and effective antibiotics to tackle rising resistance. Others, like AstraZeneca and Boehringer Ingelheim, also invest in research to innovate and improve their product offerings. Sandoz and Hikma Pharmaceuticals specialize in generics, making treatments more accessible. Meanwhile, Amgen and Gilead Sciences focus on unique therapies to meet specific medical needs. Overall, these companies are striving to enhance their positions through collaboration, research, and expanding their product lines to address global health challenges.

Recent Developments:

In September 2024, Agilent Technologies Inc. finalized its acquisition of BIOVECTRA, a Canadian contract development and manufacturing organization (CDMO) that focuses on biologics, highly potent active pharmaceutical ingredients, and other compounds for targeted therapies.

In August 2024, Bora Pharmaceuticals Co., Ltd. strategically invested in Tanvex Biopharma Co., Ltd. As part of this partnership, Bora Biologics, a subsidiary of Bora that specializes in large molecule CDMO, will merge its biomanufacturing facilities with Tanvex to establish a global service for the development and supply of biologics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PEPTIDE ANTIBIOTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Baxter International Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Fujifilm Diosynth Biotechnologies
  • Hikma Pharmaceuticals PLC
  • Polymun Scientific GmbH
  • Sandoz International GmbH (a Novartis division)
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Hoffmann-La Roche Ltd.
  • Vitae Pharmaceuticals, Inc.
  • Thermo Fisher Scientific Inc.
  • CureVac AG

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Ribosomal Synthesized Peptide Antibiotics
  • Non-Ribosomal Synthesized Peptide Antibiotics

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

  • Skin Infection
  • HABP/VABP
  • Blood Stream Infection
  • Others

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Topical
  • Others

GLOBAL PEPTIDE ANTIBIOTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Peptide Antibiotics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Peptide Antibiotics Market Snippet by Product Type
    • 2.1.2. Peptide Antibiotics Market Snippet by Disease
    • 2.1.3. Peptide Antibiotics Market Snippet by Route of Administration
    • 2.1.4. Peptide Antibiotics Market Snippet by Country
    • 2.1.5. Peptide Antibiotics Market Snippet by Region
  • 2.2. Competitive Insights

3. Peptide Antibiotics Key Market Trends

  • 3.1. Peptide Antibiotics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Peptide Antibiotics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Peptide Antibiotics Market Opportunities
  • 3.4. Peptide Antibiotics Market Future Trends

4. Peptide Antibiotics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Peptide Antibiotics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Peptide Antibiotics Market Landscape

  • 6.1. Peptide Antibiotics Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Peptide Antibiotics Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Ribosomal Synthesized Peptide Antibiotics
    • 7.1.3. Non-Ribosomal Synthesized Peptide Antibiotics

8. Peptide Antibiotics Market - By Disease

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease, 2023 & 2032 (%)
    • 8.1.2. Skin Infection
    • 8.1.3. HABP/VABP
    • 8.1.4. Blood Stream Infection
    • 8.1.5. Others

9. Peptide Antibiotics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Topical
    • 9.1.5. Others

10. Peptide Antibiotics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Peptide Antibiotics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Peptide Antibiotics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Peptide Antibiotics Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Peptide Antibiotics Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Peptide Antibiotics Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Peptide Antibiotics Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Baxter International Inc.
    • 11.2.2. Novartis AG
    • 11.2.3. Merck & Co., Inc.
    • 11.2.4. AstraZeneca PLC
    • 11.2.5. Boehringer Ingelheim GmbH
    • 11.2.6. Fujifilm Diosynth Biotechnologies
    • 11.2.7. Hikma Pharmaceuticals PLC
    • 11.2.8. Polymun Scientific GmbH
    • 11.2.9. Sandoz International GmbH (a Novartis division)
    • 11.2.10. Bristol-Myers Squibb Company
    • 11.2.11. Eli Lilly and Company
    • 11.2.12. Amgen Inc.
    • 11.2.13. Gilead Sciences, Inc.
    • 11.2.14. Hoffmann-La Roche Ltd.
    • 11.2.15. Vitae Pharmaceuticals, Inc.
    • 11.2.16. Thermo Fisher Scientific Inc.
    • 11.2.17. CureVac AG

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us